Quantcast
Last updated on April 16, 2014 at 12:15 EDT

Upsher-Smith Receives Tentative NDA Approval for Vogelxo(TM) (testosterone) Gel CIII

August 16, 2013

MAPLE GROVE, Minn., Aug. 16, 2013 /PRNewswire/ — Upsher-Smith Laboratories, Inc., today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo(TM) (testosterone) gel for topical use CIII.

(Logo: http://photos.prnewswire.com/prnh/20130520/NY17281LOGO )

About Upsher-Smith
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals. Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women’s health. For more information, visit www.upsher-smith.com.

SOURCE Upsher-Smith Laboratories, Inc.


Source: PR Newswire